Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Martek Biosciences---- future biotech cash cow! -- Ignore unavailable to you. Want to Upgrade?

To: A.J. Mullen who wrote (168)	10/23/1998 1:17:00 AM
From: nestegg	Respond to of 258

MATK seems to rise on very low volume (?). Does that means stockholders and stakeholders (insiders) are holding onto to their shares until price meets much higher in the 52 week range; which is as of today.... 52-week range: 5 3/8 - 18 3/4 ?

To: A.J. Mullen who wrote (168)	10/23/1998 9:38:00 AM
From: Robert Douglas	Read Replies (1) \| Respond to of 258

The news on CF sounds incredible.( martekbio.com )If like results are achieved in humans it could serve as a wake up call to the medical establishment (Are you listening FDA?) that these fatty acids are some of the most critical substances to the health of human beings. The cystic fibrosis market is tiny and will not create a huge market for Martek's products but it is the message that DHA is indeed “essential” that will possibly turn the tide and result in wider acceptance of DHA in the health community. -Robert